Announcements Trials
Browse Landscape

Phase

Phase 1 27Phase 3 24Phase 2 24Phase 1/2 18Phase EARLY_PHASE1 2Phase 4 2Phase NA 1Phase 2/3 1

Status

Unknown 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Multiple Myeloma 19Solid Tumor 18Breast Neoplasms 14Sarcoma 13Head and Neck Neoplasms 13Colorectal Neoplasms 13Neoplasms 12Lymphoma, B-Cell 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Melanoma 10Lymphoma 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Prostatic Neoplasms 7Leukemia 7Burkitt Lymphoma 7Advanced Solid Tumors 7Ovarian Neoplasms 6Hematologic Neoplasms 6Glioblastoma 6Recurrence 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Neoplasm Metastasis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × Myeloproliferative Disorders × Clear all
NCT03795779 2021-05-19

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

iCell Gene Therapeutics

Phase EARLY_PHASE1 Unknown
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04156256 2019-11-12

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

iCell Gene Therapeutics

Phase EARLY_PHASE1 Unknown
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡